Instructions for Flosteron (Betamethasone) [Diprospan] suspension for injection
English product name
Flosteron
Release Form
Injection suspension
Description Diprospan
Injection suspension 1 ml
betamethasone dinatria phosphate 2 mg
betamethasone dipropionate 5 mg
1 ml - ampoules (5) - packages of contour plastic (1) - packs of cardboard.
ATC codes
H02AB01 Betamethasone
Clinical-pharmacological groups / Group affiliation
GCS for injection - combination of depo-form and fast form
Active substance
betamethasone dinatria phosphate
betamethasone dipropionate
Pharmaco-therapeutic group Diprospan
Glucocorticosteroid
Storage Conditions
Store the drug in a place protected from light, at a temperature not higher than 25 ° C. Store in a place not accessible to children.
Best before date
The shelf life is three years.
Do not use the drug after the expiry date.
Pharmacological effect Diprospan
Betamethasone is a synthetic GCS that inhibits the release of interleukin-1, interleukin-2, gamma interferon from lymphocytes and macrophages. It has anti-inflammatory, anti-allergic, desensitizing, anti-shock, anti-toxic and immuno-depressive effects. It suppresses the release of pituitary ACTH and beta-lipotropin, but does not reduce the level of circulating beta-endorphin. Inhibits the secretion of thyroid hormone (TGT) and follichul-stimulating hormone (FSH).
Testimony Diprospan
- Local treatment:
- Intrauterine and perioarticular administration in inflammatory rheumatic diseases (rheumatoid arthritis, seronegative
- spondyloarthritis, arthritis in systemic connective tissue diseases), in post-traumatic arthritis, in psoriatic arthritis with multiple
- joint lesions and tendosinitis, in crystalline arthritis;
- intrauterine administration in degenerative rheumatic diseases, especially in the presence of synovitis (not used in hip arthrosis);
- inflammatory lesions of parotid tissues (bursitis, tendonitis, tendosinovite, epicondylitis, plantar fasciitis);
- introduction to the lesion site for the treatment of skin diseases in rare cases (if there is no reaction to other methods of local
- therapy): sclerosing folliculitis, keloids, ring granulema, skin sarcoidosis, diabetic lipodystrophy (liponecrosis), psoriasis, focal
- alopecia, flat red lichai, neurodermite, monoid eczema, disc red lupus.
- Systemic treatment:
systemic Flosterone effect is used in some pronounced allergic diseases: allergic rhinitis, asthmatic status, Quincke edema, allergic reactions to drugs and serums, insect bites.
Method of use, course and dosage Diprospan
The route of administration is parenteral (intra-articular, near-articular, intra-skin administration, administration to the affected tissue area and, in exceptional situations, in/m administration).
The dose for adults and children should be determined individually, depending on the size of the joint, severity, nature of the disease and the patient's reaction.
Intra-articular and near-articular introduction:
very large joints (hip) - one - two ml;
large joints (wheeled, shoulder, ankle) - one ml;
Medium size joints (elbow, wrist) - 0.5-1 ml;
Small joints (pectoral and clavicle, five phalanges, interphalanges) - 0.25-0.5 ml. For acute podagric arthritis, 0.5 to 1 ml is used.
- Nosology (ICD codes)
- J30.1
- Allergic rhinitis caused by plant pollen
- J30.3
- Other allergic rhinitis (year-round allergic rhinitis)
- J46
- Asthmatic status [status asthmaticus]
- L20.8
- Other atopic dermatitis (neurodermatitis, eczema)
- L28.0
- Simple chronic lychee (limited neurodermatitis)
- L30.0
- Monetoid eczema
- L40
- Psoriasis
- L43
- Lishay red flat
- L63
- Palatal alopecia
- L91.0
- Hypertrophic scar
- L93.0
- Red lupus erythematosus
- L94.0
- Localized scleroderma [morphea]
- M05
- Seropositive rheumatoid arthritis
- M07
- Psoriatic and enteropathic arthropathy
- M10
- Podagra
- M15
- Polyarthrosis
- M65
- Synovitis and tenosinovites
- M70
- Soft tissue diseases related to load, overload and pressure
- M71
- Other bursopathy
- M72
- Fibroplastic abnormalities
- M77
- Other Entesopathy (epicondylitis)
- M79.0
- Rheumatism unspecified
- T78.3
- Angioneurotic edema (Quincke edema)
- T88.7
- Pathological reaction to a drug or medicines unspecified